Header Logo

Connection

Jeff Slezak to Prostatectomy

Back to Details
This is a "connection" page, showing publications Jeff Slezak has written about Prostatectomy.
Jeff Slezak
Connection Strength
2.440
Prostatectomy
  1. Healthcare utilization in men with poorer sexual and urinary function recovery following robot-assisted radical prostatectomy. World J Urol. 2018 Jan; 36(1):21-26.
    View in: PubMed
    Score: 0.147
  2. Effect of a Smoking Cessation Program on Sexual Function Recovery Following Robotic Prostatectomy at Kaiser Permanente Southern California. Perm J. 2017; 21:16-138.
    View in: PubMed
    Score: 0.139
  3. The effect of urologist experience on choosing active surveillance for prostate cancer. World J Urol. 2015 Nov; 33(11):1701-6.
    View in: PubMed
    Score: 0.123
  4. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View in: PubMed
    Score: 0.118
  5. Impact of median lobe anatomy: does its presence affect surgical margin rates during robot-assisted laparoscopic prostatectomy? J Endourol. 2012 May; 26(5):457-60.
    View in: PubMed
    Score: 0.097
  6. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7.
    View in: PubMed
    Score: 0.082
  7. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
    View in: PubMed
    Score: 0.075
  8. Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. J Urol. 2008 Jan; 179(1):130-5.
    View in: PubMed
    Score: 0.074
  9. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
    View in: PubMed
    Score: 0.071
  10. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006 Nov; 68(5):1042-5.
    View in: PubMed
    Score: 0.069
  11. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8.
    View in: PubMed
    Score: 0.068
  12. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol. 2006 Sep; 176(3):1118-21.
    View in: PubMed
    Score: 0.068
  13. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 01; 107(3):521-9.
    View in: PubMed
    Score: 0.068
  14. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006 Aug; 176(2):559-63.
    View in: PubMed
    Score: 0.068
  15. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
    View in: PubMed
    Score: 0.067
  16. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol. 2006 Mar; 175(3 Pt 1):952-7.
    View in: PubMed
    Score: 0.066
  17. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
    View in: PubMed
    Score: 0.065
  18. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
    View in: PubMed
    Score: 0.062
  19. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8.
    View in: PubMed
    Score: 0.060
  20. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
    View in: PubMed
    Score: 0.060
  21. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
    View in: PubMed
    Score: 0.056
  22. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002 Sep 15; 95(6):1215-9.
    View in: PubMed
    Score: 0.052
  23. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002 Aug; 168(2):525-9.
    View in: PubMed
    Score: 0.051
  24. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan; 167(1):117-22.
    View in: PubMed
    Score: 0.049
  25. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
    View in: PubMed
    Score: 0.047
  26. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol. 2000 Aug; 18(15):2862-8.
    View in: PubMed
    Score: 0.045
  27. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
    View in: PubMed
    Score: 0.044
  28. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc. 1999 Dec; 74(12):1214-20.
    View in: PubMed
    Score: 0.043
  29. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer. 1999 Nov 01; 86(9):1775-82.
    View in: PubMed
    Score: 0.042
  30. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999 Apr; 161(4):1223-7; discussion 1227-8.
    View in: PubMed
    Score: 0.041
  31. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar; 161(3):857-62; discussion 862-3.
    View in: PubMed
    Score: 0.040
  32. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 1998 Nov 15; 83(10):2164-71.
    View in: PubMed
    Score: 0.040
  33. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997 Nov; 50(5):733-9.
    View in: PubMed
    Score: 0.037
  34. Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. BJU Int. 2017 10; 120(4):520-529.
    View in: PubMed
    Score: 0.036
  35. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1734-43.
    View in: PubMed
    Score: 0.019
  36. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
    View in: PubMed
    Score: 0.018
  37. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006 Feb; 175(2):547-51.
    View in: PubMed
    Score: 0.016
  38. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
    View in: PubMed
    Score: 0.015
  39. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 2002 Aug; 34(4):363-71.
    View in: PubMed
    Score: 0.013
  40. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
    View in: PubMed
    Score: 0.012
  41. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164(5):1591-5.
    View in: PubMed
    Score: 0.011
  42. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
    View in: PubMed
    Score: 0.010
  43. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol. 1999 Jul; 23(7):803-8.
    View in: PubMed
    Score: 0.010
  44. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
    View in: PubMed
    Score: 0.010
  45. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999 Mar 15; 85(6):1293-9.
    View in: PubMed
    Score: 0.010
  46. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998 Dec; 22(12):1491-500.
    View in: PubMed
    Score: 0.010
  47. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer. 1998 Mar 01; 82(5):902-8.
    View in: PubMed
    Score: 0.009
  48. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):222-9.
    View in: PubMed
    Score: 0.009

© 2024 Kaiser Permanente